Conference "Tumor Markers: Fundamental and Clinical Aspects" with participation of RCMG researchers
III National Conference with international participation "Tumor markers: fundamental and clinical aspects" was held July 1-4, 2021 in Gorno-Altaisk. Heads of the Department of Oncogenetics, Institute of Higher and Further Vocational Education, and Epigenetics Laboratory, FSBI RCMG, were involved in the program committee of the Conference (D.S. Mikhailenko, V.V. Strelnikov). Employees of these units made presentations every day at the Conference. V.V. Strelnikov, Head of Epigenetics Laboratory, “Collisions of disorders of methylation and gene expression in malignant neoplasms"; T.V. Kekeeva, Lead researcher of the Epigenetics Laboratory, "Analysis of HRD homologous recombination deficiency in ovarian cancer"; D.S. Mikhailenko, Head of Oncogenetics Department, "Somatic mutations as diagnostic and prognostic criteria in bladder and prostate tumors"; E.O. Ignatova, Assistant professor of the Department of Oncogenetics, "Molecular Tumor Board: partnership of molecular biologists with clinicians"; A.V. Semyanikhina, Assistant professor of the Department of Oncogenetics, "Gene-phenotypic characteristics, survival rate and prognosis in patients with Lynch syndrome: data from the FSBI N.N. Blokhin Cancer Research Centre. The roundtable discussions were held on the interaction of professional associations and problems of postgraduate medical education in oncogenetics with participation of S.A. Tyulyandin, Chairman of RUSSCO, E.V. Pechkovsky, Vice-President of Medical Laboratory Diagnostics Association, D.S. Mikhailenko, Head of Department of Oncogenetics of Institute of Higher and Further Vocational Education, M.A. Godkov, President of Laboratory Medicine Federation and A.M. Ivanov, Vice-President of LMF.
In the course of discussion, D.S. Mikhailenko made a report emphasizing the urgency of preserving and developing the Laboratory Genetics specialty, which is especially important for quality training of specialists in molecular genetic diagnosis in oncology, as well as the advisability of developing advanced training programs and guidelines with colleagues from RUSSCO, LMF, MLDA and other medical associations.